Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
PHASE2CompletedINTERVENTIONAL
Enrollment
60
Participants
Timeline
Start Date
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG
Bimosiamose
DRUG
Placebo
Trial Locations (1)
Unknown
Insaf - Respiratory Research Institute GmbH, Wiesbaden
All Listed Sponsors
lead
Revotar Biopharmaceuticals AG
INDUSTRY
NCT01108913 - Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter